RadNet, Inc. (RDNT) reported that its lung artificial intelligence subsidiary, Aidence, and Google Health, a division of Alphabet, Inc. (GOOG), announced an agreement to license Google Health’s AI research model for lung nodule malignancy prediction on CT imaging. Aidence will develop, validate and bring this model to the market to support the early and accurate diagnosis of lung cancer and the reduction of unnecessary procedures in screening programs. Aidence and Google Health intend to complete an AI application for lung nodule malignancy prediction. In this collaboration, Google Health will provide its scientific expertise. Aidence will further develop the model into a solution for clinical practice and bring it to market, complying with relevant data privacy requirements and regulatory standards. The development of this AI application is a statement of intent and no regulatory market applications have been made and no orders for sale are being taken.
Published first on TheFly
Read More on RDNT:
- RadNet, Inc. to Present at the BofA Securities 2022 Leveraged Finance Conference on November 29, 2022
- RadNet still sees 2022 revenue $1.36B-$1.41B, consensus $1.4B
- RadNet reports Q3 adjusted EPS 9c, consensus 16c
- RadNet Acquires a Controlling Interest in Heart & Lung Imaging Limited, a London-Based Teleradiology Network Focused on Lung Cancer Screening
- RadNet, Inc. Announces Date of its Third Quarter 2022 Financial Results Conference Call